Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755204 · ClinicalTrials.gov registry record
A Pharmacist-run PrEP Program for Women
A clinical trial, sponsored by Orlando Immunology Center.
- Terminated
- Registry status
- 2
- Enrollment target
NCT05755204: Clinical Trial study, sponsored by Orlando Immunology Center.
NCT05755204 is a clinical trial that was terminated before completion, run by Orlando Immunology Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05755204 was terminated before completion, sponsored by Orlando Immunology Center.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also include reasons for lack of retention in PrEP care)
Primary Outcome
proportion of women who initiate LA-CAB vs. TDF/FTC for PrEP
Interventions
- DRUG TDF/FTC
- DRUG LA-CAB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-10-15 |
Why NCT05755204 stopped before completion
NCT05755204 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which TDF/FTC is the first listed.
NCT05755204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05755204 about?
NCT05755204 is a clinical study titled "A Pharmacist-run PrEP Program for Women". The primary objective of this study is to evaluate uptake and retention of long acting cabotegravir (LA-CAB) also known as Apretude versus daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) also known as Truvada for PrEP among high-risk women in metro-Orlando through week 48 (to also i...
What is the current status of trial NCT05755204?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2023-06-21. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT05755204?
The interventions under investigation include: TDF/FTC (DRUG), LA-CAB (DRUG).
Who is sponsoring clinical trial NCT05755204?
This trial is sponsored by Orlando Immunology Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI